By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later ...

Shares in Novo Nordisk fell as much as 6% on Friday to their lowest since August 2021, extending recent losses to wipe out ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background.

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants ...

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. The GLP-1 obesity med soared to the top of the month’s ranking of TV drug ad spenders ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Novo Nordisk submitted the 7.2 mg dose of Wegovy to offer a tailored option for people with obesity who need greater weight loss support.

Wegovy belongs to a group of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. It contains the active ingredient semaglutide, which mimics the activity of our brain’s natural GLP-1.